Hemispherx Biopharma, Inc. - HEB

Exclusive Interview: Dr. William A. Carter, of Hemispherx Biopharma, Inc. (AMEX:HEB)

Pasadena, CA - 06/12/09 - BioMedReports.Com, the news portal covering the biomedical sector that delivers financial and investment intelligence to a community of highly informed investors has conducted an exclusive interview with Dr. William A. Carter, CEO of Hemispherx Biopharma (AMEX:HEB).

The exclusive audio interview, was conducted on Friday afternoon (06/12/09) and will be available at BioMedReports.Com at 8pm EST on Friday, June 12, 2009.

Dr. Carter, the co-inventor of Ampligen®, joined the Company in 1978, and has served as HEB’s Company’s Chief Scientific Officer since May 1989, the Chairman of the Company’s Board of Directors since January 1992, the Company’s Chief Executive Officer since July 1993, the Company’s President since April, 1995, and a director since 1987. From 1987 to 1988, Dr. Carter served as the Company’s Chairman. Dr. Carter was a leading innovator in the development of human interferon for a variety of treatment indications including various viral diseases and cancer. In this context, he received the first FDA approval to initiate clinical trials on a beta interferon product manufactured in the U.S. under his supervision.

Investors are invited to listen to the interview about the company, including questions about the pending FDA decision. The latest business developments and news involving Ampligen and Alferon in the influenze space as well as HEB’s intentions for new investments and expansion.

Visit BioMedReports.Com for more details.

Biotech investors interested in seeing the complete database of clinical trials and upcoming FDA decisions can access that information here:

http://biomedreports.com/component/content/article/548.html

Disclosure: No positions.


BiomedReports: Decipering Hemispherx (Amex:HEB)

Investors still waiting for FDA approval.

Published on June 10, 2009

by BiomedReports.Com Staff & Wire Reports

(BioMedReports.com and OfficialWire)

LOS ANGELES, CA

BioMedReports.Com, the news portal covering the biomedical sector that delivers financial and investment intelligence to a community of highly informed investors has initiated a report on Hemispherx Biopharma (Amex:HEB).

The end of the trading day came on Tuesday.  There was still no news of approval or denial from the FDA. Hemispherx Biopharma's (AMEX:HEB) Ampligen for Chronic Fatigue Syndrome spends yet another day in limbo.

By now, surely some of the company's investors are starting to feel like some of  CEO, Dr. William Carter's patients.

Tired... Exhausted, even.

In the words of one blog, "Ampligen for Chronic Fatigue Syndrome: Another Deadline Come & Gone."

Then, an after hours suprise. 

As filed with the Securties and Exchange Commission on June 9th, Form S-3 from Hemispherx Biopharma, Inc. let it known that they are looking for a $150 million mixed securities shelf and that the offering would include common as well as preferred stock, warrants and debt securities.

The roller coaster ride known as HEB continues to thrill.

Investors are invited to read the complete article on the company and it's latest developments at BioMedReports.Com:

http://biomedreports.com/articles/most-popular/1220-deciphering-hemispherx.html

Biotech investors interested in seeing the complete database of clinical trials and upcoming FDA decisions can access that information here:

http://biomedreports.com/component/content/article/548.html

Disclosure: No positions.
     
####
Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Presents Influenza Prevention / Treatment Platform at International Conference in Rome under Auspices of Italian Government

Company Accelerates Collaborations with Governmental, Academic and Pharmaceutical Groups to Prevent Pandemic Influenza

PHILADELPHIA, June 1, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE Amex:HEB) announced today an invitation, funded entirely by the government of Italy, to present its technology platform for influenza control, at the upcoming "International Conference on Biotechnologies and Finance" in Rome on June 4-5, 2009, at the Sheraton Parco de Medici. According to the Conference Organizers, leaders of "private and public research centers, intellectual property holders and financial experts from Europe, Australia, Canada, Estonia, Singapore and the USA" will participate. Hemispherx will present in a Round Table Discussion on Pandemic Influenza, moderated by Dr. Elemer Piros, Senior Pharmaceutical Analyst at Rodman and Renshaw, a USA investment bank.

Hemispherx has a broad-based technology platform for confronting the potential of an influenza pandemic, which consists of both preventative (vaccine) components as well as experimental therapeutic interventions. Clinical results from trials conducted in Australia are being evaluated and major vaccine initiatives in Japan are being accelerated in collaboration with the Japanese National Institutes of Health and the Japanese Ministry of Health.

About Hemispherx Biopharma

Hemispherx Biopharma, Inc. is a specialty pharma company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection(r) (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics, Ampligen(r) and Oragens. Ampligen(r) and Oragens represent experimental RNA nucleic acids being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has in excess of 50 issued patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection(r)). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net.

Hemispherx Biopharma Press Release for
Friday, June 12, 2009
Hemispherx’s Collaborative Partner in Japan, Biken Corp., Expands Production Capacity for Swine/Avian Flu Vaccines

…WHO Raises Threat of Swine Flu to Pandemic Level

Philadelphia, PA, Friday, June 12, 2009: Hemispherx Biopharma (NYSE AMEX: HEB) announced today that its collaborative influenza vaccine development partner in Japan, Biken, has decided to expand its Flu production capacity significantly.

On June 9, 2009, Biken issued the following press release in Japan (translated as follows): “Biken decided to expand its manufacturing facilities in Kanonji City. Biken will invest a total of 35 billion Yen (US $350 million) expecting to complete in 2013. Manufacturing capacities will be scaled up by 5 times, so as to be ready to manufacture Swine/Avian Flu vaccine for 60 million people within 6 months. New facilities will focus on the cell culture technology instead of the current poultry egg culture”.

According to Japanese research teams, directed by Dr. Hasegawa of the Japanese National Institute of Infectious Diseases (JNIID) and as published in a various peer-reviewed publications and presented at scientific conferences, Ampligen®, an experimental therapeutic, is an essential co-ingredient to provide experimental efficacy with the Biken vaccine. An updated peer reviewed list of the JNIID publications on this topic is being made available by accessing the Hemispherx web site: www.hemispherx.net.

Hemispherx has a broad global portfolio of pending intellectual property on the subject which includes both field of therapeutic use and composition of elemental matter on Ampligen®, an experimental therapeutic, as well as its congeners (closely related compounds).

Yesterday, the World Health Organization (WHO) raised the threat level of swine flu to its highest level, level 6.